If you or your teen has been diagnosed with peanut allergy, you may be eligible to take part in a new study exploring whether an investigational medicine called IGNX001 can help treat peanut allergy in teens and adults.
Overview
The phase 1, randomised, double-blind study will evaluate the safety and tolerability of an injectable, allergen-specific antibody that targets peanut protein.
The study is recruiting participants at:
- Fiona Stanley Hospital (Western Australia)
- St Vincent’s Hospital (New South Wales)
- The Royal Melbourne Hospital (Victoria)
- Monash Health (Victoria)
Who can take part?
To pre-qualify for this study, you or your teen must:
- Be 15 to 55 years old
- Have a history of peanut allergy, including having experienced a serious allergic reaction to peanut in the past 15 years
- Be willing to avoid peanuts and other allergy inducing foods during the study.
You or your teen cannot take part if you have:
- A history of severe or life-threatening anaphylaxis requiring admission to the intensive care unit within the last year
- A history of severe or uncontrolled asthma within the past six months
- Any clinically significant liver, kidney, cardiac or mast cell disease or uncontrolled chronic disease
- Received food allergen immunotherapy treatment or participated in a similar study in the past 12 months
What’s involved in the study
The study runs for up to six months, and involves:
- Regular visits to your study centre
- Receiving up to four injections
- Undertaking a series of tests and assessments to monitor your health during the study, including your medical history, prior and current medications, physical exams, blood and urine samples, electrocardiograms (ECG), skin prick tests and peanut oral food challenges.
Further information
For further information, go to: https://www.iggenix.com.au/
Source: IgGenix ACCELERATE Peanut Study — IgGenix
